LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 14

Search options

  1. Article ; Online: Recommendations of the Spanish Society of Pediatric Cardiology and Congenital Heart Diseases for the prevention of respiratory syncytial virus infections with nirsevimab in pediatric cardiology.

    Medrano López, Constancio / Centeno Malfaz, Fernando / Garcés Sánchez, María

    Anales de pediatria

    2024  Volume 100, Issue 2, Page(s) 148–150

    MeSH term(s) Child ; Humans ; Respiratory Syncytial Virus Infections/drug therapy ; Respiratory Syncytial Virus Infections/prevention & control ; Antibodies, Monoclonal, Humanized/therapeutic use ; Heart Defects, Congenital ; Cardiology
    Chemical Substances nirsevimab (VRN8S9CW5V) ; Antibodies, Monoclonal, Humanized
    Language English
    Publishing date 2024-01-19
    Publishing country Spain
    Document type Case Reports
    ZDB-ID 2830901-7
    ISSN 2341-2879 ; 2341-2879
    ISSN (online) 2341-2879
    ISSN 2341-2879
    DOI 10.1016/j.anpede.2023.10.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Chylothorax in newborns after cardiac surgery: a rare complication?

    Pérez-Pérez, Alba / Vigil-Vázquez, Sara / Gutiérrez-Vélez, Ana / Solís-García, Gonzalo / López-Blázquez, María / Zunzunegui Martínez, Jose Luis / Medrano López, Constancio / Gil-Jaurena, Juan Miguel / de Agustín-Asensio, Juan Carlos / Sánchez-Luna, Manuel

    European journal of pediatrics

    2023  Volume 182, Issue 4, Page(s) 1569–1578

    Abstract: The aim of this study was to analyze patients diagnosed with chylothorax after congenital heart disease surgery among a cohort of neonatal patients, comparing the evolution, complications, and prognosis after surgery of patients who were and were not ... ...

    Abstract The aim of this study was to analyze patients diagnosed with chylothorax after congenital heart disease surgery among a cohort of neonatal patients, comparing the evolution, complications, and prognosis after surgery of patients who were and were not diagnosed with chylothorax, and to analyze possible risk factors that may predict the appearance of chylothorax in this population. Retrospective and observational study included all neonates (less than 30 days since birth) who underwent congenital heart disease surgery in a level III neonatal intensive care department. We included infants born between January 2014 and December 2019. We excluded those infants who were born before 34 weeks of gestational age or whose birth weight was less than 1800 g. We also excluded catheter lab procedures and patent ductus arteriosus closure surgeries. Included patients were divided into two groups depending on whether they were diagnosed with chylothorax or not after surgery, and both groups were compared in terms of perinatal-obstetrical information, surgical data, and NICU course after surgery. We included 149 neonates with congenital heart disease surgery. Thirty-one patients (20.8%) developed chylothorax, and in ten patients (32.3%), it was considered large volume chylothorax. Regarding the evolution of these patients, 22 infants responded to general dietetic measures, a catheter procedure was performed in 9, and 5 of them finally required pleurodesis. Cardiopulmonary bypass, median sternotomy, and delayed sternal closure were the surgical variables associated with higher risks of chylothorax. Patients with chylothorax had a longer duration of inotropic support and mechanical ventilation and took longer to reach full enteral feeds. As complications, they had higher rates of cholestasis, catheter-related sepsis, and venous thrombosis. Although there were no differences in neonatal mortality, patients with chylothorax had a higher rate of mortality after the neonatal period. In a multiple linear regression model, thrombosis and cardiopulmonary bypass multiplied by 10.0 and 5.1, respectively, the risk of chylothorax and have an umbilical vein catheter decreases risk.
    Conclusion: We have found a high incidence of chylothorax after neonatal cardiac surgery, which prolongs the average stay and causes significant morbidity and mortality. We suggested that chylothorax could be an underestimated complication of congenital heart disease surgery during the neonatal period.
    What is known: • Acquired chylothorax in the neonatal period usually appears as a complication of congenital heart disease surgery, being the incidence quite variable among the different patient series (2.5-16.8%). The appearance of chylothorax as a complication of a cardiac surgery increases both mortality and morbidity in these patients, which makes it a quality improvement target in the postsurgical management of this population.
    What is new: •Most of the published studies include pediatric patients of all ages, from newborns to teenagers, and there is a lack of studies focusing on neonatal populations. The main strength of our study is that it reports, to the best of our knowledge, one of the largest series of neonatal patients receiving surgery for congenital heart disease in the first 30 days after birth. We have found a high incidence of chylothorax after cardiac surgery during the neonatal period compared to other studies. We suggested that chylothorax could be an underestimated complication of congenital heart disease surgery during this period of life.
    MeSH term(s) Infant ; Adolescent ; Humans ; Child ; Infant, Newborn ; Retrospective Studies ; Chylothorax/epidemiology ; Chylothorax/etiology ; Chylothorax/therapy ; Cardiac Surgical Procedures/adverse effects ; Heart Defects, Congenital/surgery ; Heart Defects, Congenital/diagnosis ; Risk Factors
    Language English
    Publishing date 2023-01-17
    Publishing country Germany
    Document type Observational Study ; Journal Article
    ZDB-ID 194196-3
    ISSN 1432-1076 ; 0340-6199 ; 0943-9676
    ISSN (online) 1432-1076
    ISSN 0340-6199 ; 0943-9676
    DOI 10.1007/s00431-023-04808-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Short- and long-term survival of children treated with ventricular assist devices in Spain, based on 15 years' experience.

    Menéndez, Juan José / Sánchez-Galindo, Amelia Caridad / Balcells, Joan / Tejero-Hernández, María Ángeles / Ferrer-Barba, Ángela / Ibiza-Palacios, Emilio / Medrano-López, Constancio / Gran, Ferran / Frías-Pérez, Manuel Ángel / García-Vieites, María / Cano-Sánchez, Ana / Polo, Luz / Gil-Jaurena, Juan-Miguel / Abella, Raúl Felipe / Merino-Cejas, Carlos / Martínez-Bendayán, Isaac / Serrano, Félix / García-Guereta, Luis

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

    2023  Volume 63, Issue 2

    Abstract: Objectives: To describe the use of ventricular assist devices (VAD) in children in Spain and to identify variables related to survival.: Methods: This is an observational cohort study of all children younger than 18 years of age who underwent an ... ...

    Abstract Objectives: To describe the use of ventricular assist devices (VAD) in children in Spain and to identify variables related to survival.
    Methods: This is an observational cohort study of all children younger than 18 years of age who underwent an initial implantation of a VAD at any of the 6 paediatric heart transplant centres from May 2006 to December 2020. Subjects were identified retrospectively from each hospital's database.
    Results: Paracorporeal VADs were implanted in 118 children [pulsatile (63%), continuous (30.5%) or both types (5.9%)]. Small children (<0.7 m2 of body surface area) comprised the majority of this cohort (63.3%). Overall, 67% survived to VAD explantation, and 64.9% survived to hospital discharge. Non-central nervous system haemorrhage (39%) and stroke (38.1%) were the most common complications. Body weight <5 kg, congenital heart disease, pre-implantation bilirubin >34 μmol/l and bridge to decision strategy were associated with a higher mortality at hospital discharge and in the long-term. Interagency registry for mechanically assisted circulatory support (INTERMACS) status 1 and cardiac arrest prior to VAD implantation were related to long-term mortality, whereas pre-implantation renal replacement therapy and extracorporeal membrane oxygenation were not related to mortality.
    Conclusions: In Spain, 67% of the VAD-supported children have been bridged to heart transplantation or to recovery. Body weight lower than 5 kg, congenital heart disease diagnosis, cholestatic liver dysfunction, bridge to decision as VAD strategy, INTERMACS-1 status and cardiac arrest were pre-implantation variables related to mortality, whereas pre-implantation renal replacement therapy and extracorporeal membrane oxygenation were not.
    MeSH term(s) Child ; Humans ; Heart Failure/therapy ; Heart-Assist Devices ; Retrospective Studies ; Spain ; Heart Transplantation ; Heart Defects, Congenital ; Heart Arrest ; Treatment Outcome
    Language English
    Publishing date 2023-02-09
    Publishing country Germany
    Document type Observational Study ; Journal Article
    ZDB-ID 639293-3
    ISSN 1873-734X ; 1010-7940 ; 1567-4258
    ISSN (online) 1873-734X
    ISSN 1010-7940 ; 1567-4258
    DOI 10.1093/ejcts/ezad050
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Fetal cardiology, the frontier of pediatric cardiovascular medicine.

    Medrano-Lopez, Constancio / Fouron, Jean-Claude

    Revista espanola de cardiologia (English ed.)

    2012  Volume 65, Issue 8, Page(s) 700–704

    MeSH term(s) Adult ; Arrhythmias, Cardiac/diagnosis ; Arrhythmias, Cardiac/therapy ; Cardiology/trends ; Female ; Fetal Heart/physiology ; Heart Defects, Congenital/diagnosis ; Heart Defects, Congenital/therapy ; Heart Function Tests ; Humans ; Pregnancy ; Pregnancy, High-Risk
    Language Spanish
    Publishing date 2012-08
    Publishing country Spain
    Document type Editorial
    ISSN 1885-5857
    ISSN (online) 1885-5857
    DOI 10.1016/j.recesp.2012.03.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Community-acquired respiratory infections in young children with congenital heart diseases in the palivizumab era: the Spanish 4-season civic epidemiologic study.

    Medrano López, Constancio / García-Guereta, Luis

    The Pediatric infectious disease journal

    2010  Volume 29, Issue 12, Page(s) 1077–1082

    Abstract: Introduction: To investigate the epidemiology of acute respiratory tract infections (ARIs) in children younger than 24 months old with hemodynamically significant congenital heart diseases. Primary aim: incidence of hospital admission due to ARI. ... ...

    Abstract Introduction: To investigate the epidemiology of acute respiratory tract infections (ARIs) in children younger than 24 months old with hemodynamically significant congenital heart diseases. Primary aim: incidence of hospital admission due to ARI. Secondary aims: risk factors, etiologic agents, clinical outcomes, and usefulness of preventive measures.
    Patients and methods: Prospective, multicenter, epidemiologic study conducted in 57 Spanish hospitals covering four 7-month seasons (2004-2008).
    Results: A total of 2613 patients were eligible for the study. Three hundred fifty-four patients (13.5%) (95% confidence interval: 12.3-14.9) required a total of 453 hospital admissions. Clinical diagnoses: bronchiolitis (54.1%), upper respiratory tract infection (21%), pneumonia (19.9%), and others (17.4%). Median length of hospital stay: 7.0 days. No etiologic agent was identified in two-thirds of the patients. In the remaining patients either a single agent (26.8%) or polymicrobial infection (5%) was identified. Respiratory syncytial virus (RSV) was the agent that was most commonly found (3.8% specific hospitalization rate). Children receiving adequate RSV prophylaxis (90.5%) had a 58.2% (95% confidence interval: 37.6-78.3) reduction in RSV hospitalization. Risk factors for admission included malnourishment, infant age, male gender, chromosome alterations, wheezing, inadequate RSV prophylaxis fulfillment, and siblings <11 years of age. Pediatric intensive care unit care was required in 21.8% of the admissions and 9 patients (0.34%) died.
    Conclusions: Hospital admission rate and severity of ARI remain as important issues in hemodynamically significant congenital heart disease patients. The strict fulfillment of prophylactic recommendations against RSV is the only protective factor that can be modulated to decrease the ARI hospital admission rate.
    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Antiviral Agents/therapeutic use ; Community-Acquired Infections/epidemiology ; Community-Acquired Infections/pathology ; Female ; Heart Diseases/complications ; Heart Diseases/congenital ; Hospitalization/statistics & numerical data ; Humans ; Incidence ; Infant ; Infant, Newborn ; Male ; Palivizumab ; Respiratory Tract Infections/epidemiology ; Respiratory Tract Infections/pathology ; Spain/epidemiology ; Virus Diseases/epidemiology ; Virus Diseases/pathology
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antiviral Agents ; Palivizumab (DQ448MW7KS)
    Language English
    Publishing date 2010-12
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ZDB-ID 392481-6
    ISSN 1532-0987 ; 0891-3668
    ISSN (online) 1532-0987
    ISSN 0891-3668
    DOI 10.1097/INF.0b013e3181efdac5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain.

    Schmidt, Ralph / Majer, Istvan / García Román, Natalia / Rivas Basterra, Alejandra / Grubb, ElizaBeth / Medrano López, Constancio

    Health economics review

    2017  Volume 7, Issue 1, Page(s) 47

    Abstract: Background: Respiratory syncytial virus (RSV) infection remains one of the major reasons of re-hospitalization among children with congenital heart disease (CHD). This study estimated the cost-effectiveness of palivizumab prophylaxis versus placebo, in ... ...

    Abstract Background: Respiratory syncytial virus (RSV) infection remains one of the major reasons of re-hospitalization among children with congenital heart disease (CHD). This study estimated the cost-effectiveness of palivizumab prophylaxis versus placebo, in Spain, from the societal perspective, using a novel cost-effectiveness model reflecting evidence-based clinical pathways.
    Methods: A decision-analytic model, combining a decision tree structure in the first year and a Markov structure in later years, was constructed to evaluate the benefits and costs associated with palivizumab versus no prophylaxis among children with CHD. In the first year of the model, children were at risk of mild (i.e. medically attended, MA-RSV) and severe (hospitalized, RSV-H) RSV infection. The impact of delayed corrective CHD surgery due to RSV infection and the consequence of performed surgery despite severe infection were considered. In later years, patients were at risk of developing asthma and allergic sensitization as sequelae of RSV infection. Input data for the model were derived from the pivotal clinical trial and systematic literature reviews. Indirect costs included parental absence from work and nosocomial infections. In agreement with Spanish guidelines, costs and effects were discounted at 3%.
    Results: Over a lifetime horizon, palivizumab prophylaxis yielded 0.11 and 0.07 additional quality-adjusted life years (QALYs) and life years (LYs), respectively, at additional costs of € 1,693, resulting in an ICER of € 15,748 per QALY gained and € 24,936 per LY gained. Probabilistic sensitivity analyses demonstrated that the probability of palivizumab prophylaxis being cost-effective at a € 30,000 per QALY threshold was 92.7%. The ICER remained below this threshold for most extreme scenario analyses.
    Conclusions: The model demonstrated that palivizumab prophylaxis results in more QALYs than no prophylaxis in children with CHD. Palivizumab prophylaxis was shown to be a cost-effective health care intervention according to the commonly accepted standards of cost-effectiveness in Spain (ICER below the threshold of € 30,000 per QALY).
    Language English
    Publishing date 2017-12-19
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2634483-X
    ISSN 2191-1991
    ISSN 2191-1991
    DOI 10.1186/s13561-017-0181-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Experience With the Absorb Bioresorbable Vascular Scaffold in Various Scenarios of Congenital Heart Disease.

    Rodríguez Ogando, Alejandro / Ballesteros Tejerizo, Fernando / Sarnago Cebada, Fernando / Medrano López, Constancio / Gil Jaurena, Juan Miguel / Zunzunegui Martínez, José Luis

    Revista espanola de cardiologia (English ed.)

    2017  Volume 71, Issue 11, Page(s) 988–990

    MeSH term(s) Absorbable Implants ; Child ; Child, Preschool ; Female ; Heart Defects, Congenital/surgery ; Humans ; Infant ; Infant, Newborn ; Male ; Prosthesis Design ; Tissue Scaffolds ; Treatment Outcome
    Language Spanish
    Publishing date 2017-10-05
    Publishing country Spain
    Document type Letter
    ISSN 1885-5857
    ISSN (online) 1885-5857
    DOI 10.1016/j.rec.2017.08.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: H1N1 influenza vaccination and infection in pediatric heart transplants.

    Vázquez-Álvarez, Maria del Carmen / Medrano-López, Constancio / Camino-López, Manuela

    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

    2010  Volume 29, Issue 11, Page(s) 1318

    MeSH term(s) Adolescent ; Child ; Child, Preschool ; Female ; Heart Transplantation/immunology ; Humans ; Immunosuppression ; Incidence ; Infant ; Influenza A Virus, H1N1 Subtype/immunology ; Influenza, Human/epidemiology ; Influenza, Human/prevention & control ; Male ; Retrospective Studies ; Risk Factors ; Spain ; Treatment Outcome ; Viral Vaccines/therapeutic use
    Chemical Substances Viral Vaccines
    Language English
    Publishing date 2010-11
    Publishing country United States
    Document type Letter
    ZDB-ID 1062522-7
    ISSN 1557-3117 ; 1053-2498
    ISSN (online) 1557-3117
    ISSN 1053-2498
    DOI 10.1016/j.healun.2010.07.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: CHD and respiratory syncytial virus: global expert exchange recommendations.

    Tulloh, Robert M R / Medrano-Lopez, Constancio / Checchia, Paul A / Stapper, Claudia / Sumitomo, Naokata / Gorenflo, Matthias / Jung Bae, Eun / Juanico, Antonio / Gil-Jaurena, Juan M / Wu, Mei-Hwan / Farha, Talal / Dodge-Khatami, Ali / Tsang, Rocky / Notario, Gerard / Wegzyn, Colleen

    Cardiology in the young

    2017  Volume 27, Issue 8, Page(s) 1504–1521

    Abstract: Background: Palivizumab is the standard immunoprophylaxis against serious disease due to respiratory syncytial virus infection. Current evidence-based prophylaxis guidelines may not address certain children with CHD within specific high-risk groups or ... ...

    Abstract Background: Palivizumab is the standard immunoprophylaxis against serious disease due to respiratory syncytial virus infection. Current evidence-based prophylaxis guidelines may not address certain children with CHD within specific high-risk groups or clinical/management settings.
    Methods: An international steering committee of clinicians with expertise in paediatric heart disease identified key questions concerning palivizumab administration; in collaboration with an additional international expert faculty, evidence-based recommendations were formulated using a quasi-Delphi consensus methodology.
    Results: Palivizumab prophylaxis was recommended for children with the following conditions: <2 years with unoperated haemodynamically significant CHD, who are cyanotic, who have pulmonary hypertension, or symptomatic airway abnormalities; <1 year with cardiomyopathies requiring treatment; in the 1st year of life with surgically operated CHD with haemodynamically significant residual problems or aged 1-2 years up to 6 months postoperatively; and on heart transplant waiting lists or in their 1st year after heart transplant. Unanimous consensus was not reached for use of immunoprophylaxis in children with asymptomatic CHD and other co-morbid factors such as arrhythmias, Down syndrome, or immunodeficiency, or during a nosocomial outbreak. Challenges to effective immunoprophylaxis included the following: multidisciplinary variations in identifying candidates with CHD and prophylaxis compliance; limited awareness of severe disease risks/burden; and limited knowledge of respiratory syncytial virus seasonal patterns in subtropical/tropical regions.
    Conclusion: Evidence-based immunoprophylaxis recommendations were formulated for subgroups of children with CHD, but more data are needed to guide use in tropical/subtropical countries and in children with certain co-morbidities.
    Language English
    Publishing date 2017-10
    Publishing country England
    Document type Journal Article
    ZDB-ID 1078466-4
    ISSN 1467-1107 ; 1047-9511
    ISSN (online) 1467-1107
    ISSN 1047-9511
    DOI 10.1017/S1047951117000609
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Actualización en cardiología pediátrica y cardiopatías congénitas.

    Medrano López, Constancio / Guía Torrent, José Manuel / Rueda Núñez, Fernando / Moruno Tirado, Antonio

    Revista espanola de cardiologia

    2008  Volume 62 Suppl 1, Page(s) 39–52

    Abstract: The fields of pediatric cardiology and congenital heart disease have experienced considerable progress in the last few years, with advances in new diagnostic and therapeutic techniques that can be applied at all stages of life from the fetus to the adult. ...

    Title translation Update on pediatric cardiology and congenital heart disease.
    Abstract The fields of pediatric cardiology and congenital heart disease have experienced considerable progress in the last few years, with advances in new diagnostic and therapeutic techniques that can be applied at all stages of life from the fetus to the adult. This article reviews scientific publications in a number of areas that appeared between August 2007 and September 2008. In developed countries, congenital heart disease is becoming increasingly prevalent in nonpediatric patients, including pregnant women. Actions aimed at preventing coronary heart disease must be started early in infancy and should involve the promotion of a healthy diet and lifestyle. Recent developments in echocardiography include the introduction of three-dimensional echocardiography and of new techniques such as two-dimensional speckle tracking imaging, which can be used for both anatomical and functional investigations in patients with complex heart disease, including a univentricular heart. Progress has also occurred in fetal cardiology, with new data on prognosis and prognostic factors and developments in intrauterine interventions, though indications for these interventions have still to be established. Heart transplantation has become a routine procedure, supplemented in some cases by circulatory support devices. In catheter interventions, new devices have become available for the closure of atrial or ventricular septal defects and patent ductus arteriosus as well as for percutaneous pulmonary valve implantation. Surgery is also advancing, in some cases with hybrid techniques, particularly for the treatment of hypoplastic left heart syndrome. The article ends with a review of publications on cardiomyopathy, myocarditis and the treatment of bacterial endocarditis.
    MeSH term(s) Cardiac Surgical Procedures ; Cardiology/trends ; Child ; Echocardiography ; Endocarditis/therapy ; Fetal Heart/diagnostic imaging ; Heart Defects, Congenital/therapy ; Heart Diseases/prevention & control ; Heart Transplantation ; Humans ; Myocarditis/therapy ; Pediatrics/trends
    Language Spanish
    Publishing date 2008-12-18
    Publishing country Spain
    Document type Journal Article ; Review
    ZDB-ID 128925-1
    ISSN 1579-2242 ; 0300-8932
    ISSN (online) 1579-2242
    ISSN 0300-8932
    DOI 10.1016/s0300-8932(09)70040-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top